(Amoxicillin + omeprazole magnesium+ rifabutin) DR is a Small Molecule owned by RedHill Biopharma, and is involved in 6 clinical trials, which were completed.

Amoxicillin is a semisynthetic aminopenicillin antibiotic with bactericidal activity. Amoxicillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis.

Omeprazole Magnesium is the magnesium salt form of a benzimidazole with selective and irreversible proton pump inhibitor activity. In the acidic compartment of parietal cells, omeprazole is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.

Rifabutin inhibits DNA-dependent RNA polymerase in susceptible strains of Escherichia coli and Bacillus subtilis but not in mammalian cells. In resistant strains of E. coli, rifabutin, like rifampin, did not inhibit this enzyme. It is not known whether rifabutin inhibits DNA-dependent RNA polymerase in Mycobacterium avium or in M. intracellulare which comprise M. avium complex (MAC).

Omeprazole is a proton pump inhibitor. Rifabutin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Rifabutin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.  Amoxicillin binds to and inactivates penicillin-binding protein (PBP) 1A located on the inner membrane of the bacterial cell wall and inhibits the third and last stage of bacterial cell wall synthesis. The proton pump inhibitors work by completely blocking the production of stomach acid. They do this by inhibiting a system in the stomach known as the proton pump. Proton pump inhibitors act by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system of the gastric parietal cell.

The revenue for (Amoxicillin + omeprazole magnesium+ rifabutin) DR is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Amoxicillin + omeprazole magnesium+ rifabutin) DR NPV Report.

(Amoxicillin + omeprazole magnesium+ rifabutin) DR is currently owned by RedHill Biopharma.

(Amoxicillin + omeprazole magnesium+ rifabutin) DR Overview

Amoxicillin, Omeprazole Magnesium and Rifabutin (Talicia) is a fixed dose combination, that acts as an antibiotic and anti-ulcer agent. It is formulated as delayed release hard gelatin capsules for oral route of administration.Talicia is indicated for the treatment of Helicobacter pylori infection.

RedHill Biopharma Overview

RedHill Biopharma (RedHill) is a specialty biopharmaceutical company that develops and commercializes therapeutics for gastrointestinal (GI) diseases and cancer. The company’s commercial product portfolio consists of branded prescription drugs including a combination of omeprazole, amoxicillin and rifabutinomeprazole; naloxegol; and rifamycin. It is investigating its pipeline candidates for the treatment of Crohn’s disease, non-tuberculous mycobacterial infection (NTM) infections, gastroenteritis, gastritis, irritable bowel syndrome with diarrhea (IBS-D), bowel cleanser, cancer and novel coronavirus disease (COVID-19). The company has a subsidiary in the US. RedHill is headquartered in Tel Aviv, Israel.

The company reported revenues of (US Dollars) US$85.8 million for the fiscal year ended December 2021 (FY2021), an increase of 33.2% over FY2020. The operating loss of the company was US$81.1 million in FY2021, compared to an operating loss of US$63.7 million in FY2020. The net loss of the company was US$97.7 million in FY2021, compared to a net loss of US$76.2 million in FY2020. The company reported revenues of US$17.6 million for the third quarter ended September 2022, a decrease of 4.3% over the previous quarter.

Quick View – (Amoxicillin + omeprazole magnesium+ rifabutin) DR

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Amoxicillin + omeprazole magnesium+ rifabutin) DR
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.